SG11201911512SA - Agent for preventing or treating brain atrophy - Google Patents
Agent for preventing or treating brain atrophyInfo
- Publication number
- SG11201911512SA SG11201911512SA SG11201911512SA SG11201911512SA SG11201911512SA SG 11201911512S A SG11201911512S A SG 11201911512SA SG 11201911512S A SG11201911512S A SG 11201911512SA SG 11201911512S A SG11201911512S A SG 11201911512SA SG 11201911512S A SG11201911512S A SG 11201911512SA
- Authority
- SG
- Singapore
- Prior art keywords
- preventing
- agent
- treating brain
- brain atrophy
- atrophy
- Prior art date
Links
- 208000024806 Brain atrophy Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017109885 | 2017-06-02 | ||
JP2017128472 | 2017-06-30 | ||
JP2017145100 | 2017-07-27 | ||
PCT/JP2018/021223 WO2018221729A1 (ja) | 2017-06-02 | 2018-06-01 | 脳萎縮予防または治療剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201911512SA true SG11201911512SA (en) | 2020-01-30 |
Family
ID=64455855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201911512SA SG11201911512SA (en) | 2017-06-02 | 2018-06-01 | Agent for preventing or treating brain atrophy |
Country Status (15)
Country | Link |
---|---|
US (1) | US11951092B2 (ja) |
EP (1) | EP3632431A4 (ja) |
JP (2) | JP7282028B2 (ja) |
KR (1) | KR20190137936A (ja) |
CN (3) | CN116473962A (ja) |
AU (1) | AU2018276638B2 (ja) |
BR (1) | BR112019024851A2 (ja) |
CA (1) | CA3067453C (ja) |
IL (1) | IL270922A (ja) |
MX (1) | MX2019014310A (ja) |
NZ (1) | NZ759585A (ja) |
RU (1) | RU2759727C2 (ja) |
SG (1) | SG11201911512SA (ja) |
WO (1) | WO2018221729A1 (ja) |
ZA (1) | ZA201907973B (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ759585A (en) * | 2017-06-02 | 2022-02-25 | Fujifilm Toyama Chemical Co Ltd | Agent for preventing or treating brain atrophy |
WO2018221732A1 (ja) | 2017-06-02 | 2018-12-06 | 富山化学工業株式会社 | アミロイドβ蛋白質量減少剤 |
NZ759647A (en) | 2017-06-02 | 2022-02-25 | Fujifilm Toyama Chemical Co Ltd | Agent for preventing or treating spinocerebellar ataxia |
JPWO2018221728A1 (ja) | 2017-06-02 | 2020-04-02 | 富士フイルム富山化学株式会社 | アルツハイマー型認知症予防または治療剤 |
US11548878B2 (en) | 2017-10-30 | 2023-01-10 | Fujifilm Toyama Chemical Co., Ltd. | Emopamil binding protein binding agent and use thereof |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2302808C (en) | 1997-09-05 | 2010-05-18 | Human Genome Sciences, Inc. | 50 human secreted proteins |
GB9824207D0 (en) | 1998-11-04 | 1998-12-30 | Zeneca Ltd | Neurological disorders |
BRPI0213393B8 (pt) | 2001-10-19 | 2021-05-25 | Fujifilm Toyama Chemical Co Ltd | derivados de éter alquílico, ou um de seus sais, processo para produzir um derivado de éter alquílico, derivado de alquil-amida, ou um de seus sais, e, composição farmacêutica |
SI2389937T1 (sl) | 2002-06-14 | 2018-10-30 | Toyama Chemical Co., Ltd, | Farmacevtska sestava za izboljšanje možganske funkcije |
AU2004229283B2 (en) | 2003-04-17 | 2009-02-05 | Toyama Chemical Co., Ltd. | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof |
US8119625B2 (en) * | 2006-04-26 | 2012-02-21 | Toyama Chemical Co., Ltd. | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
SI2011796T1 (sl) * | 2006-04-26 | 2015-02-27 | Toyama Chemical Co., Ltd. | Induktor nevrogeneze ali terapevtska uäśinkovina proti nevropatiji, vsebujoäśa derivat alkilnega etra ali sol le-tega |
NZ587532A (en) | 2008-03-04 | 2012-07-27 | Vernalis R&D Ltd | Azetidine derivatives for inhibition of faah activity |
FR2934596B1 (fr) | 2008-07-30 | 2015-04-10 | Trophos | Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation |
NO2419104T3 (ja) | 2009-04-13 | 2018-04-07 | ||
JP5808319B2 (ja) | 2009-05-11 | 2015-11-10 | フォルム ファーマシューティカルズ、インコーポレイテッド | アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα7ニコチン酸受容体を用いた認知障害の治療 |
US20110262442A1 (en) | 2009-11-06 | 2011-10-27 | Adenios, Inc. | Compositions for treating cns disorders |
CN104159583B (zh) * | 2012-02-22 | 2018-04-13 | 富山化学工业株式会社 | 含有1‑(3‑(2‑(1‑苯并噻吩‑5‑基)乙氧基)丙基)氮杂环丁烷‑3‑醇或其盐的固体药物组合物 |
AU2013292519B2 (en) | 2012-07-19 | 2017-12-07 | Drexel University | Sigma receptor ligands for modulating cellular protein homeostasis |
EP2903980B1 (en) | 2012-10-01 | 2017-07-19 | F. Hoffmann-La Roche AG | Benzimidazoles as cns active agents |
LT3100725T (lt) * | 2014-01-31 | 2020-08-10 | Fujifilm Toyama Chemical Co., Ltd. | Reabilitacijos poveikį po nervo pažeidimo sustiprinanti priemonė, apimanti alkileterio darinį arba jo druską |
WO2015163318A1 (ja) | 2014-04-25 | 2015-10-29 | レジリオ株式会社 | アルツハイマー病の治療剤を含む、神経細胞の軸索の機能不全が関与する疾患の治療剤 |
WO2015188368A1 (en) | 2014-06-13 | 2015-12-17 | Merck Sharp & Dohme Corp. | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles |
WO2016051799A1 (ja) | 2014-10-01 | 2016-04-07 | 学校法人同志社 | 2-アミノヒドロキノン誘導体及びタウ凝集阻害剤 |
SG11201705727TA (en) | 2015-02-02 | 2017-08-30 | Ucb Biopharma Sprl | 9h-pyrrolo-dipyridine derivatives |
US20160324851A1 (en) | 2015-05-07 | 2016-11-10 | Axovant Sciences, Ltd. | Methods of treating a neurodegenerative disease |
EP3308782B1 (en) | 2015-06-11 | 2022-01-19 | Toyama Chemical Co., Ltd. | Sigma-receptor binding agent |
KR102703879B1 (ko) | 2015-12-25 | 2024-09-05 | 후지필름 도야마 케미컬 가부시키가이샤 | 1-(3-(2-(1-벤조티오펜-5-일)에톡시)프로필)아제티딘-3-올 또는 그 염을 포함하는 정제 |
NZ759585A (en) * | 2017-06-02 | 2022-02-25 | Fujifilm Toyama Chemical Co Ltd | Agent for preventing or treating brain atrophy |
JPWO2018221728A1 (ja) | 2017-06-02 | 2020-04-02 | 富士フイルム富山化学株式会社 | アルツハイマー型認知症予防または治療剤 |
NZ759647A (en) | 2017-06-02 | 2022-02-25 | Fujifilm Toyama Chemical Co Ltd | Agent for preventing or treating spinocerebellar ataxia |
WO2018221731A1 (ja) | 2017-06-02 | 2018-12-06 | 富山化学工業株式会社 | タウオパチー予防または治療剤 |
WO2018221732A1 (ja) | 2017-06-02 | 2018-12-06 | 富山化学工業株式会社 | アミロイドβ蛋白質量減少剤 |
US11548878B2 (en) | 2017-10-30 | 2023-01-10 | Fujifilm Toyama Chemical Co., Ltd. | Emopamil binding protein binding agent and use thereof |
-
2018
- 2018-06-01 NZ NZ759585A patent/NZ759585A/en unknown
- 2018-06-01 CN CN202310470444.0A patent/CN116473962A/zh active Pending
- 2018-06-01 RU RU2019138166A patent/RU2759727C2/ru active
- 2018-06-01 BR BR112019024851A patent/BR112019024851A2/pt unknown
- 2018-06-01 CN CN201880035394.0A patent/CN110709078A/zh active Pending
- 2018-06-01 CN CN202310474317.8A patent/CN116492335A/zh active Pending
- 2018-06-01 AU AU2018276638A patent/AU2018276638B2/en active Active
- 2018-06-01 SG SG11201911512SA patent/SG11201911512SA/en unknown
- 2018-06-01 KR KR1020197035347A patent/KR20190137936A/ko not_active IP Right Cessation
- 2018-06-01 MX MX2019014310A patent/MX2019014310A/es unknown
- 2018-06-01 WO PCT/JP2018/021223 patent/WO2018221729A1/ja active Application Filing
- 2018-06-01 EP EP18810520.9A patent/EP3632431A4/en active Pending
- 2018-06-01 CA CA3067453A patent/CA3067453C/en active Active
- 2018-06-01 US US16/617,739 patent/US11951092B2/en active Active
- 2018-06-01 JP JP2019521348A patent/JP7282028B2/ja active Active
-
2019
- 2019-11-25 IL IL270922A patent/IL270922A/en unknown
- 2019-11-29 ZA ZA2019/07973A patent/ZA201907973B/en unknown
-
2023
- 2023-02-15 JP JP2023021443A patent/JP2023053337A/ja not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN116492335A (zh) | 2023-07-28 |
CN110709078A (zh) | 2020-01-17 |
EP3632431A1 (en) | 2020-04-08 |
AU2018276638B2 (en) | 2021-04-08 |
NZ759585A (en) | 2022-02-25 |
CN116473962A (zh) | 2023-07-25 |
JPWO2018221729A1 (ja) | 2020-04-09 |
RU2759727C2 (ru) | 2021-11-17 |
IL270922A (en) | 2020-01-30 |
US20200215030A1 (en) | 2020-07-09 |
ZA201907973B (en) | 2022-03-30 |
MX2019014310A (es) | 2022-06-10 |
RU2019138166A (ru) | 2021-07-09 |
JP7282028B2 (ja) | 2023-05-26 |
WO2018221729A1 (ja) | 2018-12-06 |
CA3067453C (en) | 2021-11-23 |
EP3632431A4 (en) | 2020-06-03 |
US11951092B2 (en) | 2024-04-09 |
KR20190137936A (ko) | 2019-12-11 |
CA3067453A1 (en) | 2018-12-06 |
JP2023053337A (ja) | 2023-04-12 |
RU2019138166A3 (ja) | 2021-07-09 |
BR112019024851A2 (pt) | 2020-06-09 |
AU2018276638A1 (en) | 2019-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB201715639D0 (en) | Compositions for wound treatment | |
SG11201705767PA (en) | Agent for preventing and/or treating amyotrophic lateral sclerosis | |
ZA201907973B (en) | Agent for preventing or treating brain atrophy | |
IL262825A (en) | Tetrahydropyridine and tetrahydropyrimidine substances, preparations containing them and their use for pain treatment | |
GB201709402D0 (en) | Compounds for treating t-pll | |
IL271256A (en) | Preparations and methods for the treatment of teopathy | |
GB2567616B (en) | Treatment method | |
ZA201907975B (en) | Agent for preventing or treating tauopathy | |
ZA201906047B (en) | Compounds for treating tuberculosis | |
GB2571601B (en) | Treatment method | |
ZA201907974B (en) | Agent for preventing or treating spinocerebellar ataxia | |
SG11202012055PA (en) | Methods and compositions for preventing or treating calciphylaxis | |
IL291266A (en) | Preparations and methods for treating infections | |
ZA201907283B (en) | Compositions, devices and methods for treating autism | |
PL3426237T3 (pl) | Sposób leczenia zaniku mózgu | |
GB202214988D0 (en) | Compositions and methods for preventing or treating nephrolithiasis | |
SG11202001806TA (en) | Treatment method | |
IL270867A (en) | Treatment method | |
SG11202004642YA (en) | An agent for treating nocturnal pollakiuria | |
IL271967A (en) | Methods for treating congenital hypersecretion of insulin | |
EP3432884A4 (en) | COMBINATIONS FOR THE TREATMENT OF PAIN | |
SG11202103619QA (en) | Methods for treating or preventing skin conditions | |
RS62891B1 (sr) | Kompozicija za lečenje konstipacije | |
ZA201805215B (en) | Preparation for nasal-nasopharyngeal treatment | |
GB201711677D0 (en) | Combination treatment |